Merck & Co., Inc. is 85.5x more valuable than NewAmsterdam Pharma Company N.V. by market capitalization ($293.16 B vs $3.43 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NAMS | MRK |
|---|---|---|
| Market cap | $3.43 B | $293.16 B |
| US-listed rank | #1703 | #44 |
| Revenue (latest FY) | $22.50M | $65.01B |
| Net income (latest FY) | -$203.00M | $18.25B |
| Net margin | -902.1% | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 386 | 996 |
Merck & Co., Inc. is 85.5x more valuable than NewAmsterdam Pharma Company N.V. by market capitalization ($293.16 B vs $3.43 B).
In their latest fiscal years, NewAmsterdam Pharma Company N.V. reported $22.50M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: NewAmsterdam Pharma Company N.V. and Merck & Co., Inc., or browse the full rankings.